Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr Parisa Zamiri as its Chief Medical Officer, effective immediately. Dr. Zamiri brings with her extensive experience in biopharmaceutical and small molecule drug discovery and development, drug and device safety, pharmacovigilance, and biomarker development across various therapeutic areas.
Dr. Zamiri joins CTx from Graybug Vision, Inc., where she held the position of Chief Medical Officer and was…
Astex Expands Drug Discovery Collaboration With MSD
Cambridge, UK, 8 August 2023, Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, today announced an exclusive worldwide research collaboration and license agreement with MSD (Merck & Co., Inc., Rahway, N.J., USA). The goal of the collaboration is to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer.
“Astex is applying its…
Dear One Nucleus members,
We are delighted to invite you to Collaborate and Network with your Local Community using Connexn - a new online platform to make team-building easy and intuitive. Created by Cambridge University members and alumni and free to use, Connexn allows easy connection for scientists, entrepreneurs, and creatives in Cambridge and beyond.
Make connections within the area that is right for you and get help with your hands-on project now!
Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech company and a UK university.
The University of Leicester has joined forces with Cambridge-based Isogenica to develop new immunotherapies – a process where the patient’s immune system is helped to fight cancer – which will be tested on a ‘virtual patient’.
The virtual patient will be created in the laboratory, by taking samples of a patient’s own tumour cells and immune system, and will then be presented with a range of new immunotherapies developed by the…
Congratulations to the ten startup companies who celebrated the completion of the Stevenage Bioscience Catalyst's Catalyser Programme.
During the programme, each company were supported by a team of mentors to refine their commercialisation strategies before pictching to an audience of investors, experts and invited guests.
Read more...
26th edition of the awards recognises the fastest growing technology companies in the UK
Deloitte’s 26th annual Technology Fast 50 awards is open for nominations until 1ST September. The awards rank and recognise the 50 fastest growing technology companies in the UK, based on the last four years of revenue growth. Supporting Deloitte’s initiative for the UK’s fastest growing companies are the award sponsors Oracle NetSuite, BGF and HSBC Innovation Banking.
Since 1998, the Deloitte Technology Fast 50 awards have showcased an increasingly innovative and diverse range of UK-based technology…
Huge congratulations to the Cambridge Crystallographic Data Centre (CCDC), the University of Leeds, Tianjin University, and AbbVie Inc. who recently won an Outstanding Manuscript Award from the American Association of Pharmaceutical Scientists (AAPS) for a published research paper in the scientific journal Pharmaceutical Research investigating AIDS drug Ritonavir – ‘Solid-State and Surface Structures of the Conformational Polymorphic Forms of Ritonavir in Relation to their Physicochemical Properties.’
Dr Jürgen Harter, CEO of CCDC said “This…
Domainex share their latest updates in recent newsletter including:
Receiving a King's Award for Enterprise
Expansion plans in UK and US
The launch of new Cryo-EM and Flow Cytometry services
Latest recruits
Read the full newsletter
Our August eNews is here: 'Embracing Change and Unlocking Opportunities in the Evolving Life Science Industry' ✅ This month's overview from Tony Jones, CEO, One Nucleus✅ Be at Your Best with One Nucleus Events✅ ON Helix 2023 - When do Good Neighbours become Good Business Partners?✅ One Nucleus wins Gold Award for Green Impact✅ The Evolving Role of Online Innovation Workshops via One Nucleus Read it here: https://bit.ly/3KMjntR
OMass Therapeutics Expands Leadership Team with Two New Appointments
Appointment of two senior executives in newly created roles
Peter Phillips M.D., Ph.D. joins as Senior Vice President of Clinical Development and Julia Sampson Ph.D. joins as Vice President of Non-clinical Development
Oxford, United Kingdom – 02 August 2023 – OMass Therapeutics (‘OMass’, or ‘the Company’), a biotechnology company that identifies medicines against highly validated target ecosystems, today announces the expansion of its leadership team with the appointment of two senior executives in newly…